Newsroom

On 29/09/2024, Genotypos Science Labs participated in the Greece Race For The Cure event, aiming to raise awareness about breast cancer.

GENOTYPOS SCIENCE LABS will participate in the Greece Race For The Cure on 29/09/24 at Zappeion! Let's support the fight against breast cancer together. Together, we make hashtag#almazois.

As of 05/08/2024, the test analysis under ID 8917 will be replaced by test ID 8938.

The new Encephalitis/Meningitis panel is a RT-PCR (CE-IVD) test that detects HSV-1, HSV-2, VZV, CMV, EBV, HHV-6, HHV-7, Human enterovirus, Parechovirus, Parvovirus B19 & Adenovirus.

For any clarification needed, kindly contact us at genotypos@genotypos.gr

We would like to inform you that a new test is available!

Test Name: IDH1/2 mutation detection

Test ID: 8526

Method analysis: PCR-RFLP

Mutations in the IDH1 and IDH2 genes are reported in 15% - 20% of acute myeloid leukemia (AML) cases, with IDH1 R132 and IDH2 R140 and R172 being the most clinically significant.

Accepted sample for analysis: peripheral blood or bone marrow sample in EDTA vial (4 oC)

TAT: 5 days

The test detects all mutations at codon R132 in the IDH1 gene and at codons R140 & R172 in the IDH2 gene.

We are proud to announce that a new PCR test is available for the detection of mutations in the HER2 gene (test ID#8911).

Patients with NSCLC and HER2 exon 20 insertions respond to trastuzumab (Herceptin) and dual-acting (EGFR/HER2) TKIs such as lapatinib, neratinib, and afatinib, while these mutations also render them resistant to first-generation TKIs (erlotinib and gefitinib).

At Genotypos labs we apply a commercially available panel (AmoyDx) that qualitatively detects targeted mutations in exons 19 and 20 of the HER2 gene, specifically: A775_G776insYVMA (2 variants), M774_A775insAYVM, G776>VC (2 variants), G776R, G776C, P780_Y781insGSP (4 variants), V777L, and L744P.

Accepted sample: FFPE

TAT: 5 days

For any clarification needed, kindly contact us at genotypos@genotypos.gr